The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,653.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK blocks Shell paying Iran oil debt in food, medicine

Mon, 22nd Apr 2013 12:44

By Richard Mably

LONDON, April 22 (Reuters) - Britain has blocked efforts byoil major Royal Dutch Shell to settle a $2.3 billiondebt it owes Iran by paying in kind with grains orpharmaceuticals, industry sources said.

Shell has been trying for months to find a way to workaround international sanctions that prevent it paying incurrency for crude it bought from the National Iranian OilCompany before a European Union embargo on Iran that startedlast July.

The sources said the British government was reluctant toprovide relief for the Iranian economy when Western powers areusing sanctions to apply financial pressure on Tehran todismantle its nuclear programme.

"The view is that doesn't make sense to smooth the way for apayment that helps Iran when government is trying to press Iranto negotiate," said an industry source.

A government spokesman declined comment on the Shell casebut said: "The government fully backs the tough regime of EUsanctions that have been put in place against Iran."

Talks earlier this month between Iran and six world powersincluding Britain failed to make progress in resolving adecade-old dispute around Iran's nuclear progress. Another roundof negotiations has been scheduled for May 21.

The industry sources said Shell in February explored withthe British government the possibility of asking Britishpharmaceuticals maker GSK to deliver medicines to Iranin a payment-in-kind deal known as an offset agreement.

GSK said it had not been approached or held any discussionson the matter. Shell declined comment.

In October, the Anglo-Dutch oil company sought permissionfor an offset agreement that would have seen U.S. agriculturaltrader Cargill deliver grain to Iran.

Following publication by Reuters, Dutch foreign ministerFrans Timmermans in a letter to parliament acknowledged theproposal, saying: "As in all sanctions regimes there are somecarefully defined exceptions applicable for which in certaincases an exemption can be granted by national governments."

Meetings were held with Cargill but, said the industrysources, the proposal was turned down by the British government.Cargill and Shell both declined comment at the time.

MAINTAINING IRAN RELATIONSHIP

The sources said the oil company wanted to repay its debt toNIOC to maintain cordial relations with Iran, one of the biggestproducers in the Organization of the Petroleum ExportingCountries.

"Politics come and go but it's in the interests of Shell andits shareholders to pay its debts and maintain a relationshipwith a leading oil producer like Iran," said one of the sources.

Shell revealed in a March filing to U.S. regulatoryauthorities that it owed Tehran $2.3 billion and made a net lossof $6 million trading Iranian oil in 2012. Unlike its rivals,Shell continued trading with Iran under a provision forpre-existing contracts close to the EU's June 30 deadline beforethe embargo. The debt is for oil purchased in 2011 and 2012.

Iran's oil revenues have fallen by about 50 percent sincesanctions were imposed last year, and regional economistsbelieve it has been forced to draw on its foreign reserves tohelp buy essentials like grains.

But with an estimated $100 billion of foreign reserves atthe start of 2012, thanks to high oil prices, the Iranianeconomy is far from collapse.

The International Monetary Fund said last week that whilesanctions had frozen Iran out of the international bankingsystem, Tehran was avoiding a balance-of-payments crisis andshould emerge from recession in 2014.

Food and medicine are among the humanitarian goods notbarred by U.S. and European sanctions but, isolated frominternational banking, Iran has been forced to pay a premium forgrain imports.

Washington has tried to restrict countries like China,India, South Korea and Japan that still buy Iranian oil topaying for shipments by the barter of approved goods - includingfood and medicine.

U.S. sanctions state that funds used to pay for oil mustremain in a bank account in the purchasing country and can beused only for non-sanctioned, bilateral trade between thatcountry and Iran. Any bank that repatriates the money ortransfers it to a third country faces a U.S. sanction risk.

Nevertheless, said the industry sources, it appears theBritish government would rather Iran be obliged to spend foreignreserves or use oil revenues to barter for essential importsthan benefit from shipments of humanitarian goods paid for byShell debt.

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.